Main content
Sorry, this episode is not currently available

The changing nature of pharmaceutical research

We find out how investor returns are dictating the nature of pharmaceutical research.

We find out how investor returns are dictating the nature of pharmaceutical research. Martin Hall is a neuropharmacologist and pharmacist who led a Cambridge research centre and is now at Hardman and Co, and explains how pharmaceutical giants focus on drugs with the biggest returns. Carl Sterritt is co-founder and chief executive of Shield Therapeutics, which has a promising iron tablet in the pipeline, and tells us about the challenges of bringing a drug to market. And Neil Clark, chief executive of Destiny Pharma discusses what he sees as the most promising avenues for drug development. Also in the programme, the UK government is intervening in the US takeover of British defence and aerospace firm, Cobham. Guy Anderson from Jane's Defence considers how likely it is that the sale will actually be blocked. Plus our correspondent in Switzerland reports on small scale dairy farmers' response to the Intergovernmental Panel on Climate Change urging us to cut down on dairy produce.

(Picture: An assortment of tablets. Picture credit: Getty Images.)

Release date:

26 minutes

Podcast